A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells
Mesenchymalization is a cellular and molecular program in which epithelial cells progressively lose their well-differentiated phenotype and adopt mesenchymal characteristics. Tumor mesenchymalization occurs during the progression of cancer to metastatic disease, and is also associated with resistanc...
Main Authors: | Justin M. David, Charli Dominguez, Kristen K. McCampbell, James L. Gulley, Jeffrey Schlom, Claudia Palena |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2017-10-01
|
Series: | OncoImmunology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/2162402X.2017.1349589 |
Similar Items
-
M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine
by: Karin M. Knudson, et al.
Published: (2018-05-01) -
FMNL1 down-regulation suppresses bone metastasis through reducing TGF-β1 expression in non-small cell lung cancer (NSCLC)
by: Xing-Yi Yang, et al.
Published: (2019-09-01) -
Cyclic RGD Pentapeptide Cilengitide Enhances Efficacy of Gefitinib on TGF-β1-Induced Epithelial-to-Mesenchymal Transition and Invasion in Human Non-Small Cell Lung Cancer Cells
by: Jisu Jeong, et al.
Published: (2021-03-01) -
The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer
by: Yang Zhang, et al.
Published: (2019-07-01) -
Targeting the PD-1/PD-L1 axis in the treatment of lung cancer
by: Matikas Alexios, et al.
Published: (2016-03-01)